BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.2.3.1//EN
BEGIN:VEVENT
UID:382@siliconvalleyons.org
DTSTART:20251105T023000Z
DTEND:20251105T023000Z
DTSTAMP:20251027T212834Z
URL:https://www.siliconvalleyons.org/events/imforte-regimen-the-first-and-
 only-fda-approved-combination-for-maintenance-treatment-in-1l-es-sclc-nov-
 4th/
SUMMARY:IMforte regimen: The first and only FDA-approved combination for ma
 intenance treatment in 1L ES-SCLC - Nov 4th
DESCRIPTION:For maintenance treatment in 1L extensive-stage small cell lung
  cancer\n\nOn behalf of Genentech\, you are invited to attend an expert-le
 d educational presentation: IMforte regimen: The first and only FDA-approv
 ed combination for maintenance treatment in 1L ES-SCLC\nA review of the tr
 ial data for the IMforte regimen (TECENTRIQ + lurbinectedin)\n\nIndication
 : TECENTRIQ\, in combination with lurbinectedin\, is indicated for the mai
 ntenance treatment of adult patients with ES-SCLC whose disease has not pr
 ogressed after firs t-line induction therapy with TECENTRIQ or atezolizuma
 b and hyaluronidas e-tqjs\, carboplatin and etopos ide.\n\nFeatured Facult
 y: Kathleen C. Kerrigan\, DO. Associate Professor of Medical Oncology Kath
 ryn F. Kirk Center at Hunts man Cancer Institute Salt Lake City\, UT\n\nWh
 en: Tuesday\, November 4\, 2025. Arrival Time: 6:30 pm PT. Start Time: 7:0
 0 pm PT\n\nVenue: Town\, 716 Laurel Street\, San Carlos \, CA 94070\n\nPle
 ase RSVP: by 10/30/25 to Lisa Reinmann at (415) 297-8278\n\nProgram Overvi
 ew:\n• An overview of the SCLC landscape\n• An introduction to the IMf
 orte clinical trial design\, patient characteristics\, and pivotal efficac
 y and safety data\n\nClick here to view this full event flyer
LOCATION:TOWN\, 716 Laurel St\, San Carlos\, CA\, 94070\, United States
GEO:37.5048205;-122.25949539999999
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=716 Laurel St\, San Carlos\
 , CA\, 94070\, United States;X-APPLE-RADIUS=100;X-TITLE=TOWN:geo:37.504820
 5,-122.25949539999999
END:VEVENT
END:VCALENDAR